Present situation and future prospects of endoscopic technology in the treatment of obesity

doi:10.3877/cma.j.issn.2095-2015.2025.05.001

Abstract

Abstract:

Currently, obesity has emerged as a significant global public health issue and ranks as the sixth leading risk factor for death and disability in China. Nowadays, the treatment of obesity primarily revolves around three aspects: lifestyle modification, pharmacological therapy, and bariatric and metabolic surgery. As an emerging treatment for obesity, endoscopic weight reduction technology boasts ultra-minimal invasiveness, low cost, and a reduced risk of complications, earning widespread recognition both domestically and internationally. This article briefly evaluates common endoscopic weight reduction techniques, aiming to offer novel insights into the treatment of obesity.

Key words: Obesity, Bariatric surgery, Endoscopic bariatric surgery

Jiaming Xue, Shuai Chen, Yuwen Jiao, Dongmei Wang, Jie Zhao, Yan Zhou, Liming Tang. Present situation and future prospects of endoscopic technology in the treatment of obesity[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(05): 421-425.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.05.001

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I05/421

References 56

[1]	Ellison-Barnes A, Johnson S, Gudzune K. Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018[J]. JAMA, 2021, 326(20): 2073-2074.
[2]	Abdulla M, Mohammed N, AlQamish J. Overview on the endoscopic treatment for obesity: A review[J]. World J Gastroenterol, 2023, 29(40): 5526-5542.
[3]	Collaborators GBDRF. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223-1249.
[4]	Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults[J]. Lancet, 2023, 401(10382): 1116-1130.
[5]	Look ARG, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial[J]. Arch Intern Med, 2010, 170(17): 1566-1575.
[6]	Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity[J]. Gastroenterology, 2022, 163(5): 1198-1225.
[7]	Gasoyan H, Tajeu G, Halpern MT, et al. Reasons for underutilization of bariatric surgery: The role of insurance benefit design[J]. Surg Obes Relat Dis, 2019, 15(1): 146-151.
[8]	Laing P, Pham T, Taylor L J, et al. Filling the Void: A Review of Intragastric Balloons for Obesity[J]. Dig Dis Sci, 2017, 62(6): 1399-1408.
[9]	Jirapinyo P, Hadefi A, Thompson CC, et al. American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity[J]. Endoscopy, 2024, 56(6): 437-456.
[10]	Kim SH, Chun HJ, Choi HS, et al. Current status of intragastric balloon for obesity treatment[J]. World J Gastroenterol, 2016, 22(24): 5495-5504.
[11]	Buzga M, Kupka T, Siroky M, et al. Short-term outcomes of the new intragastric balloon End-Ball((R)) for treatment of obesity[J]. Wideochir Inne Tech Maloinwazyjne, 2016, 11(4): 229-235.
[12]	Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures-2019 Update: Cosponsored by American Association of Clinical Endocrinologists/ American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists[J]. Obesity (Silver Spring), 2020, 28(4): O1-O58.
[13]	Bazerbachi F, Vargas EJ, Abu Dayyeh BK. Endoscopic Bariatric Therapy: A Guide to the Intragastric Balloon[J]. Am J Gastroenterol, 2019, 114(9): 1421-1431.
[14]	Dolan RD, Schulman AR. Endoscopic Approaches to Obesity Management[J]. Annu Rev Med, 2022, 73: 423-438.
[15]	Zerrweck C, Maunoury V, Caiazzo R, et al. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients[J]. Obes Surg, 2012, 22(5): 777-782.
[16]	Zurawinski W, Sokolowski D, Krupa-Kotara K, et al. Evaluation of the results of treatment of morbid obesity by the endoscopic intragastric balloon implantation method[J]. Wideochir Inne Tech Maloinwazyjne, 2017, 12(1): 37-48.
[17]	Kermansaravi M, Esparham A, Parmar C, et al. Intragastric Balloon as a Bridge Before Metabolic and Bariatric Surgery: A Systematic Review and Meta-analysis[J]. Obes Surg, 2025, 35(5): 1934-1946.
[18]	Reja D, Zhang C, Sarkar A. Endoscopic bariatrics: current therapies and future directions[J]. Transl Gastroenterol Hepatol, 2022, 7: 21.
[19]	Carrano FM, Peev MP, Saunders JK, et al. The Role of Minimally Invasive and Endoscopic Technologies in Morbid Obesity Treatment: Review and Critical Appraisal of the Current Clinical Practice[J]. Obes Surg, 2020, 30(2): 736-752.
[20]	Marinos G, Eliades C, Raman Muthusamy V, et al. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study[J]. Surg Obes Relat Dis, 2014, 10(5): 929-934.
[21]	Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic Bariatric and Metabolic Therapies: New and Emerging Technologies[J]. Gastroenterology, 2017, 152(7): 1791-1801.
[22]	刘南, 郭瑾陶, 孙思予. 内镜技术在减重治疗中的应用进展[J]. 中国实用内科杂志, 2023, 43(1): 78-83.
[23]	刘京丽, 田沛荣, 张鹏. 内镜减重技术进展及未来趋势[J]. 中国实用外科杂志, 2023, 43(5): 583-586.
[24]	Ahmed EM. Hydrogel: Preparation, characterization, and applications: A review[J]. J Adv Res, 2015, 6(2): 105-121.
[25]	Shirin H, Richter V, Matalon S, et al. Safety, tolerability and efficacy of a novel self-use biodegradable device for management of obesity[J]. Obes Sci Pract, 2019, 5(4): 376-382.
[26]	Pass A, Bialonczyk D, Chiquette E, et al. Oral Superabsorbent Hydrogel(Plenity) for Weight Management[J]. Ann Pharmacother, 2021, 55(9): 1146-1152.
[27]	Greenway FL, Aronne LJ, Raben A, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss[J]. Obesity(Silver Spring), 2019, 27(2): 205-216.
[28]	Nduma BN, Mofor KA, Tatang J, et al. Endoscopic Sleeve Gastroplasty(ESG) Versus Laparoscopic Sleeve Gastroplasty(LSG): A Comparative Review[J]. Cureus, 2023, 15(7): e41466.
[29]	Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity Management in Adults: A Review[J]. JAMA, 2023, 330(20): 2000-2015.
[30]	卞景愿, 朱宝成, 严斌, 等. 干预胃的内镜减重现状与发展趋势[J]. 中国普外基础与临床杂志, 2024, 31(4): 403-408.
[31]	Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up[J]. Obes Surg, 2017, 27(10): 2649-2655.
[32]	Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity(MERIT): a prospective, multicentre, randomised trial[J]. Lancet, 2022, 400(10350): 441-451.
[33]	范志宁, 王建坤. 内镜减重手术的现状和未来[J]. 外科理论与实践, 2018, 23(6): 502-505.
[34]	Miller K, Turro R, Greve JW, et al. MILEPOST Multicenter Randomized Controlled Trial: 12-Month Weight Loss and Satiety Outcomes After pose(SM) vs. Medical Therapy[J]. Obes Surg, 2017, 27(2): 310-322.
[35]	Sullivan S, Swain JM, Woodman G, et al. Randomized sham- controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial[J]. Obesity (Silver Spring), 2017, 25(2): 294-301.
[36]	Lopez-Nava G, Asokkumar R, Turro Arau R, et al. Modified primary obesity surgery endoluminal(POSE-2) procedure for the treatment of obesity[J]. VideoGIE, 2020, 5(3): 91-93.
[37]	Deviere J, Ojeda Valdes G, Cuevas Herrera L, et al. Safety, feasibility and weight loss after transoral gastroplasty: First human multicenter study[J]. Surg Endosc, 2008, 22(3): 589-598.
[38]	Verlaan T, Paulus GF, Mathus-Vliegen EM, et al. Endoscopic gastric volume reduction with a novel articulating plication device is safe and effective in the treatment of obesity(with video)[J]. Gastrointest Endosc, 2015, 81(2): 312-320.
[39]	Biertho L, Hould FS, Lebel S, et al. Transoral endoscopic restrictive implant system: a new endoscopic technique for the treatment of obesity[J]. Surg Obes Relat Dis, 2010, 6(2): 203-205.
[40]	McCarty TR, Thompson CC. The current state of bariatric endoscopy[J]. Dig Endosc, 2021, 33(3): 321-334.
[41]	Igi WF, de Oliveira VL, Matar A, et al. Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control[J]. Clin Endosc, 2024, 57(3): 309-316.
[42]	Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery[J]. Ann Surg, 2010, 251(2): 236-243.
[43]	Jirapinyo P, Haas AV, Thompson CC. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes[J]. Diabetes Care, 2018, 41(5): 1106-1115.
[44]	Zechmeister-Koss I, Huic M, Fischer S, et al. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review[J]. Obes Surg, 2014, 24(2): 310-323.
[45]	Maggi U, Formiga A, Lauro R. Hepatic abscess as a complication of duodenal-jejunal bypass sleeve system and review of the literature[J]. Surg Obes Relat Dis, 2016, 12(5): e47-e50.
[46]	Ryder REJ, Laubner K, Benes M, et al. Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1, 022 Patients Treated Worldwide[J]. Diabetes Care, 2023, 46(4): e89-e91.
[47]	Hoyt JA, Cozzi E, D'Alessio DA, et al. A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes[J]. Diabetes Obes Metab, 2024, 26(6): 2017-2028.
[48]	van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study[J]. Gut, 2020, 69(2): 295-303.
[49]	Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study[J]. Gastroenterology, 2013, 145(6): 1245-1252.e1-e5.
[50]	Thompson CC, Abu Dayyeh BK, Kushnir V, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial[J]. Surg Obes Relat Dis, 2019, 15(8): 1348-1354.
[51]	Gagner M, Fried M, Michalsky D, et al. First-in-Human Linear Magnetic Jejuno-Ileal Bipartition: Preliminary Results with Incisionless, Sutureless, Swallowable Technique[J]. Obes Surg, 2025, 35(6): 2067-2080.
[52]	Graves CE, Co C, Hsi RS, et al. Magnetic Compression Anastomosis (Magnamosis): First-In-Human Trial[J]. J Am Coll Surg, 2017, 225(5): 676-681 e671.
[53]	Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study[J]. Int J Obes(Lond), 2007, 31(4): 707-712.
[54]	Li L, Liu QS, Liu WH, et al. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial[J]. Hepatogastroenterology, 2012, 59(118): 2003-2007.
[55]	Liu J, Hou X, Song G, et al. Gastric electrical stimulation using endoscopically placed mucosal electrodes reduces food intake in humans[J]. Am J Gastroenterol, 2006, 101(4): 798-803.
[56]	Giurgius M, Fearing N, Weir A, et al. Long-term follow-up evaluation of endoscopic sclerotherapy for dilated gastrojejunostomy after gastric bypass[J]. Surg Endosc, 2014, 28(5): 1454-1459.

Please choose a citation manager

Content to export